Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia

References

• Misdrahi D, Tessier A, Swendsen J, et al. For FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group. Determination of adherence profiles in schizophrenia using self-reported adherence: results from the FACE-SZ dataset. J Clin Psychiatry. 2016;77(9):e1130–e1136. doi:10.4088/jcp.15m10115
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang W, Ma N, et al. Adherence to antipsychotic medication by community-based patients with schizophrenia in China: a cross-sectional study. Psychiatr Serv. 2016;67(4):431–437. doi:10.1176/appi.ps.201500056
   PubMed Web of Science ®Google Scholar
• Nitzan U, Bukobza G, Aviram S, et al. Rebelliousness in patients suffering from schizophrenia-spectrum disorders – a possible predictor of adherence. Psychiatr Res. 2013;209(3):297–301. doi:10.1016/j.psychres.2012.12.028
   Web of Science ®Google Scholar
• Velligan D, Weiden P, Sajatovic M, et al. For expert consensus panel on adherence problems in serious and persistent mental illness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(4):1–46.
   PubMed Web of Science ®Google Scholar
• Lieberman J, Stroup T, McEvoy J, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223. doi:10.1056/NEJMoa051688
   PubMed Web of Science ®Google Scholar
• Lacro J, Dunn L, Dolder C, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892–909. doi:10.4088/JCP.v63n1007
   PubMed Web of Science ®Google Scholar
• Barnes T, Paton C. Antipsychotic polypharmacy in schizophrenia. CNS Drugs. 2011;25(5):383–399. doi:10.2165/11587810-000000000-00000
   PubMed Web of Science ®Google Scholar
• Barkhof E, Meijer C, de Sonneville L, et al. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia–a review of the past decade. Eur Psychiatry. 2012;27(1):9–18. doi:10.1016/j.eurpsy.2011.02.005
   PubMed Web of Science ®Google Scholar
• Puschner B, Born B, Giessler A, et al. Adherence to medication and quality of life in people with schizophrenia: results of a European multicenter study. J Nerv Mental Dis. 2006;194(10):746–752. doi:10.1097/01.nmd.0000243082.75008.e7
   Web of Science ®Google Scholar
• Widschwendter C, Kemmler G, Rettenbacher M, et al. Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication. BMC Psychiatry. 2018;18(1):1–9. doi:10.1186/s12888-018-1791-y
   Web of Science ®Google Scholar
• Hofer A, Fleischhacker W. Compliance with treatment and its relevance for the management of schizophrenia. Hot Topics Neurol Psychiatr. 2011;11(1):7–13.
   Google Scholar
• Hernandez M, Barrio C. Families and medication use and adherence among Latinos with schizophrenia. J Ment Health. 2017;26(1):14–20. doi:10.1080/09638237.2016.1222061
   PubMed Web of Science ®Google Scholar
• Caqueo-Urízar A, Urzúa A, Fond G, et al. Medication non-adherence among South American patients with schizophrenia. Patient Prefer Adherence. 2017;11(1):1737–1744. doi:10.2147/PPA.S144961
   Web of Science ®Google Scholar
• Medina E, Salvà J, Ampudia R, et al. Short-term clinical stability and lack of insight are associated with a negative attitude towards antipsychotic treatment at discharge in patients with schizophrenia and bipolar disorder. Patient Prefer Adherence. 2012;6(1):623–629. doi:10.2147/PPA.S34345
   Web of Science ®Google Scholar
• Vassileva I, Milanova V. Attitudes toward antipsychotic medication, insight and psychopathology in outpatients with schizophrenia. Folia Med. 2012;54(4):62–68. doi:10.2478/v10153-012-0007-3
   Google Scholar
• Andrianarisoa M, Boyer L, Godin O, et al. Childhood trauma, depression and negative symptoms are independently associated with impaired quality of life in schizophrenia. Results from the national FACE-SZ cohort. Schizophr Res. 2017;185(1):173–181. doi:10.1016/j.schres.2016.12.021
   Web of Science ®Google Scholar
• Saleem F, Hassali M, Shafie A, et al. Does treatment adherence correlate with health related quality of life? Findings from a cross sectional study. BMC Public Health. 2012;12(1):318. doi:10.1186/1471-2458-12-318
   Web of Science ®Google Scholar
• Puschner B, Angermeyer M, Leese M, et al. Course of adherence to medication and quality of life in people with schizophrenia. Psychiatry Res. 2009;165(3):224–233. doi:10.1016/j.psychres.2007.10.011
   Web of Science ®Google Scholar
• Coldham E, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002;106(4):286–290. doi:10.1034/j.1600-0447.2002.02437.x
   PubMed Web of Science ®Google Scholar
• Velligan D, Sajatovic M, Hatch A, et al. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017;11(1):449. doi:10.2147/PPA.S124658
   Web of Science ®Google Scholar
• Adelufosi A, Adebowale T, Abayomi O, et al. Medication adherence and quality of life among Nigerian outpatients with schizophrenia. Gen Hosp Psychiatry. 2012;34(1):72–79. doi:10.1016/j.genhosppsych.2011.09.001
   PubMed Web of Science ®Google Scholar
• Endriyani L, Chien C, Huang X, et al. The influence of adherence to antipsychotics medication on the quality of life among patients with schizophrenia in Indonesia. Perspect Psychiatr Care. 2018;55(2):147–152. doi:10.1111/ppc.12276
   Web of Science ®Google Scholar
• Hayhurst K, Drake R, Massie J, et al. Improved quality of life over one year is associated with improved adherence in patients with schizophrenia. Eur Psychiatry. 2014;29:191–196. doi:10.1016/j.eurpsy.2013.03.002
   PubMed Web of Science ®Google Scholar
• Ng C, Smith D, King J, et al. Medication attitudes and beliefs in patients with psychotic and affective disorders on maintenance treatment. Hum Psychopharmacol. 2012;27(1):57–62. doi:10.1002/hup.1264
   Web of Science ®Google Scholar
• World Health Organization. ICD-10 Classifications of Mental and Behavioural Disorder: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization; 1992.
   Google Scholar
• Hogan T, Awad A, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13(1):177–183. doi:10.1017/S0033291700050182
   PubMed Web of Science ®Google Scholar
• Nielsen R, Lindström E, Nielsen J, et al. DAI-10 is as good as DAI-30 in schizophrenia. Eur Neuropsychopharmacol. 2012;22(10):747–750. doi:10.1016/j.euroneuro.2012.02.008
   PubMed Web of Science ®Google Scholar
• Saleem F, Hassali M, Shafie A, et al. Association between knowledge and drug adherence in patients with hypertension in Quetta, Pakistan. Trop J Pharm Res. 2011;10(2):125–132. doi:10.4314/tjpr.v10i2.66552
   Web of Science ®Google Scholar
• Ramírez F, Robles R, Salazar V, et al. Evaluación de actitudes al medicamento en pacientes con esquizofrenia propiedades psicométricas de la versión en español del DAI. Actas Esp Psiquiatr. 2004;32(3):138–142.
   Google Scholar
• Boyer L, Simeoni M, Loundou A, et al. The development of the S-QoL 18: a shortened quality of life questionnaire for patients with schizophrenia. Schizophr Res. 2010;121(1–3):241–250. doi:10.1016/j.schres.2010.05.019
   PubMed Web of Science ®Google Scholar
• Caqueo-Urízar A, Boyer L, Boucekine M, et al. Spanish cross-cultural adaptation and psychometric properties of the Schizophrenia Quality of Life short-version questionnaire (SQoL18) in 3 middle-income countries: Bolivia, Chile, and Peru. Schizophr Res. 2014;159(1):136–143. doi:10.1016/j.schres.2014.08.013
   Web of Science ®Google Scholar
• Carreño A. Revisiter les frontières et réparer l’histoire.Itinéraires thérapeutiques et processus de sauvegarde de la médecine traditionnelle andine dans un contexte transnational. Anthropologie Santé. 2013;6(1):1–18. doi:10.4000/anthropologiesante.1087
   Google Scholar
• Kay S, Fiszbein A, Opler L. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. doi:10.1093/schbul/13.2.261
   PubMed Web of Science ®Google Scholar
• Peralta V, Cuesta M. Validation of positive and negative symptom scale (PANSS) in a sample of Spanish schizophrenic patients. Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1994;22(4):171–177.
   PubMedGoogle Scholar
• Amador X, Strauss D. Poor insight in schizophrenia. Psychiatr Q. 1993;64(4):305–318. doi:10.1007/BF01064924
   PubMedGoogle Scholar
• Ruiz A, Pousa E, Duñó R, et al. Spanish adaptation of the Scale to Assess Unawareness of Mental Disorder (SUMD). Actas Esp Psiquiatr. 2008;36(2):111–1198.
   Web of Science ®Google Scholar
• IBM Corp. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp; 2017.
   Google Scholar
• Acosta F, Ramallo-Fariña Y, Siris S. Should full adherence be a necessary goal in schizophrenia? Full versus non-full adherence to antipsychotic treatment. Compr Psychiatry. 2014;55(1):33–39. doi:10.1016/j.comppsych.2013.09.005
   Web of Science ®Google Scholar
• Fujikawa M, Togo T, Yoshimi A, et al. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(3):755–760. doi:10.1016/j.pnpbp.2007.12.002
   PubMed Web of Science ®Google Scholar
• Arraras J, Ibañez B, Basterra I, et al. Determinants of quality of life in Spanish outpatients with schizophrenia spectrum disorders. Eur J Psychiatry. 2018;32(3):113–121. doi:10.1016/j.ejpsy.2017.11.001
   Web of Science ®Google Scholar
• Alessandrini M, Lançon C, Fond G, et al. A structural equation modelling approach to explore the determinants of quality of life in schizophrenia. Schizophr Res. 2016;171(1–3):27–34. doi:10.1016/j.schres.2016.01.012
   PubMed Web of Science ®Google Scholar
• Liu-Seifert H, Osuntokun O, Godfrey J, et al. Patient perspectives on antipsychotic treatments and their association with clinical outcomes. Patient Prefer Adherence. 2010;4:369–377. doi:10.2147/ppa.s12461
   Web of Science ®Google Scholar
• Shuler K. Approaches to improve adherence to pharmacotherapy in patients with schizophrenia. Patient Prefer Adherence. 2014;8:701–714. doi:10.2147/PPA.S59371
   PubMed Web of Science ®Google Scholar
• Boyer L, Aghababian V, Richieri R, et al. Insight into illness, neurocognition and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36(2):271–276. doi:10.1016/j.pnpbp.2011.10.008
   PubMed Web of Science ®Google Scholar
• Guedes de Pinho L, Pereira A, Chaves C. Quality of life in schizophrenic patients: the influence of sociodemographic and clinical characteristics and satisfaction with social support. Trends Psychiatry Psychother. 2018;40(3):202–209. doi:10.1590/2237-6089-2017-0002
   PubMedGoogle Scholar
• Xiang Y, Wang C, Wang Y, et al. Socio-demographic and clinical determinants of quality of life in Chinese patients with schizophrenia: a prospective study. Qual Life Res. 2010;19(3):317–322. doi:10.1007/s11136-010-9593-9
   PubMed Web of Science ®Google Scholar
• Nose M, Barbui C, Tansella M. How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychol Med. 2005;33(7):1149–1160. doi:10.1017/s0033291703008328
   Web of Science ®Google Scholar
• Adewuya A, Owoeye O, Erinfolami A, et al. Prevalence and correlates for poor medication adherence amongst psychiatric outpatients in Southwestern Nigeria. Gen Hosp Psychiatry. 2009;31(2):364–368. doi:10.1016/j.genhosppsych.2008.12.005
   Web of Science ®Google Scholar
• Adeponle A, Baduku A, Adelekan M, et al. Prospective study of psychiatric follow-up default and medication compliance after discharge at a psychiatric hospital in Nigeria. Community Ment Health J. 2009;45(1):19–25. doi:10.1007/s10597-008-9155-6
   Web of Science ®Google Scholar
• de Salud M. Guía Clínica: para el tratamiento de personas desde el primer episodio de esquizofrenia [clinical guidelines: for the treatment of people from the first episode of schizophrenia]. Santiago: MINSAL; 2016. Available from: https://www.normassalud.com/documentos/chile/guia_esquizofrenia_2017.pdf. Accessed October 20, 2016.
   Google Scholar
• Thornicroft G, Tansella M. Growing recognition of the importance of services user involvement in mental health services planning and evaluation. Epidemiol Psichiatr Soc. 2005;14(1):1–3. doi:10.1017/S1121189X00001858
   PubMed Web of Science ®Google Scholar